Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2024. The document contains an auditor's opinion on the effectiveness of internal controls related to financial reporting. It is a standalone audit report focused on internal control audit results, not a full annual report or other types of filings. The length is short (872 characters), but the content is substantive and includes an audit opinion, so it is not merely an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2024
2025-04-11 Chinese
关于董事、监事及高级管理人员2025年薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2025 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards, payment methods, and conditions for these key personnel. There is no financial data, audit information, or report content. The focus is on compensation information for top executives and board members, which fits the definition of Remuneration Information filings. The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is Remuneration Information (DEF 14A).
2025-04-11 Chinese
2024年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the year 2024 of 海思科医药集团股份有限公司. It contains detailed audit opinions, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The content is comprehensive and includes auditor responsibilities, management responsibilities, and detailed financial data. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The document is clearly a standalone audit report, not an annual report or a certification or announcement. Therefore, the correct classification is Audit Report / Information (AR). FY 2024
2025-04-11 Chinese
监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Haishike Pharmaceutical Group Co., Ltd. It details the approval of various reports and proposals including the 2024 Supervisory Board Work Report, 2024 Financial Report, 2024 Annual Report and its summary, 2024 Internal Control Self-Evaluation Report, and the 2024 Profit Distribution Plan and 2025 Mid-term Dividend Plan. The document states that these reports and proposals still require approval by the shareholders' meeting. The document is not the reports themselves but a formal announcement of the Supervisory Board's resolutions regarding these reports. It is a typical announcement of board/management decisions and resolutions rather than the full reports or financial statements. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (1273 characters), consistent with an announcement rather than a full report.
2025-04-11 Chinese
独立董事2024年度述职报告（曹传德）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company, describing their duties, attendance at board and shareholder meetings, opinions expressed, on-site inspections, investor protection efforts, training, and other related activities during the year 2024. It is a formal report on the director's management and governance role rather than a financial report or announcement. The content aligns with a Board/Management Information report, specifically focusing on the independent director's annual duties and responsibilities. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-04-11 Chinese
独立董事2024年度述职报告（岳琳）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of the company, describing their duties, attendance at board and shareholder meetings, opinions expressed, committee work, on-site inspections, investor protection efforts, and training during the year 2024. It is a formal report on the director's activities and responsibilities over the year, not an announcement or a brief notice. The content focuses on board/management information, specifically the independent director's annual work report. The document length is 2072 characters, which is relatively short but contains substantive content about management activities rather than just an announcement or certification. Therefore, the most appropriate classification is 'Board/Management Information' (MANG).
2025-04-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.